27
Participants
Start Date
September 21, 2022
Primary Completion Date
January 21, 2024
Study Completion Date
January 21, 2026
TH-SC01(Umbilical cord mesenchymal stem cells)
"5+7 principle:~1\. In medium and high dose groups, 5 subjects were included in each dose group in the first step, and the first 3 subjects had good safety The investigator evaluated safety and efficacy data and could enroll a fourth and fifth subject.~1. If the number of successful participants in these 5 subjects is less than 2, the study in this dose group will be ended due to drug ineffectiveness, and the researcher will evaluate the safety and enter the next dose group.~2. If the number of successful participants in these 5 cases is greater than or equal to 2, then proceed to the second step.~2\. 7 subjects were included in the second step."
RECRUITING
Jinling Hospital, China, Nanjing
Jiangsu Topcel-KH Pharmaceutical Co., Ltd.
INDUSTRY
Jinling Hospital, China
OTHER